[Should neoadjuvant therapy be performed for nodular breast cancer stage II-III, and if so, by which modality?].
In order to choose optimal preoperative treatment for nodular breast cancer stage II-III (T1-4N0-2M0), potentials of neoadjuvant polychemotherapy and large-fraction radiotherapy were compared (464). Groups of patients were formed by random selection. Five-year relapse-free course rates after radiotherapy were 83.0+/-3.7%, polychemotherapy - 61.9+/-4.7% (p< or =0.001) while those of survival - 86.0+/-3.5% and 67.6+/-4.6% (p< or =0.01), respectively); eight-year rates after large-fraction radiotherapy doubled (p< or =0.05). Comparatively worse results of neoadjuvant polychemotherapy could have been due to delayed (3-4 months) surgery.
Efetov
V M
VM
Dylenok
I N
IN
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis; D016896:Treatment Outcome